Massachusetts Financial Services Co. MA Takes Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Massachusetts Financial Services Co. acquired 884,691 shares (~$176.5 million) of Charles River in Q4, representing about 1.80% ownership of the company.
• Charles River beat Q4 estimates (EPS $2.39 vs. $2.33; revenue $994.2M vs. $987.0M), set FY2026 guidance of 10.700–11.200 EPS, and carries a consensus analyst rating of "Moderate Buy" with a $206.15 target.

Massachusetts Financial Services Co. MA acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 884,691 shares of the medical research company's stock, valued at approximately $176,478,000. Massachusetts Financial Services Co. MA owned about 1.80% of Charles River Laboratories International at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company's stock valued at $913,686,000 after acquiring an additional 27,989 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Charles River Laboratories International by 1.0% in the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company's stock valued at $195,446,000 after acquiring an additional 12,035 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company's stock valued at $182,017,000 after acquiring an additional 137,335 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company's stock valued at $176,909,000 after acquiring an additional 120,207 shares during the last quarter. Finally, Earnest Partners LLC boosted its holdings in shares of Charles River Laboratories International by 0.8% in the 3rd quarter. Earnest Partners LLC now owns 1,006,724 shares of the medical research company's stock valued at $157,512,000 after acquiring an additional 8,467 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $175.57 on Monday. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The firm has a market cap of $8.66 billion, a PE ratio of -59.32, a price-to-earnings-growth ratio of 2.12 and a beta of 1.61. The company's 50 day simple moving average is $170.21 and its 200-day simple moving average is $182.18. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $228.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts' consensus estimates of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. Charles River Laboratories International's quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. TD Cowen dropped their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, February 20th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Mizuho dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a report on Friday, February 20th. Barclays decreased their target price on shares of Charles River Laboratories International from $215.00 to $200.00 and set an "overweight" rating for the company in a research note on Thursday, February 19th. Finally, Citigroup increased their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $206.15.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.